3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
308
Lung Neoplasms
70
Neoplasms
50
Neoplasm Metastasis
33
Parkinson Disease 4, Autosomal Dominant Lewy Body
20
Colorectal Neoplasms
20
Carcinoma
20
Mesothelioma
15
Breast Neoplasms
15
Mesothelioma, Malignant
13
Small Cell Lung Carcinoma
11
Melanoma
10
Adenocarcinoma
10
Neoplasms by Site
9
Adenocarcinoma of Lung
8
Pancreatic Neoplasms
7
Ovarian Neoplasms
7
Lung Diseases
7
Thoracic Neoplasms
6
Squamous Cell Carcinoma of Head and Neck
6
Non-Squamous Non-Small Cell Lung Cancer
6
Uterine Cervical Neoplasms
5
Respiratory Tract Neoplasms
5
Respiratory Tract Diseases
5
Recurrence
5
Rectal Neoplasms
5
Neoplasms by Histologic Type
5
NSCLC
5
Head and Neck Neoplasms
5
Endometrial Neoplasms
5
Interventions
tremelimumab
1
durvalumab
1
Pemetrexed
1
Gemcitabine
1
Cisplatin
1
Carboplatin
1
Albumin-Bound Paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Non Small Cell Lung Cancer NSCLC
×
Pemetrexed
×
Clear all
NCT03164616
2026-03-13
POSEIDON
AstraZeneca
Phase 3
Active not recruiting
1,186 enrolled
26 charts
1 FDA